To assess the efficacy and toxicity of HAA regimen (homoharritonine 4 mg/m 2 /day, days 1-3; cytarabine 150 mg/m 2 /day, days 1-7; aclarubicin 12 mg/m 2 /day, days 1-7) as an induction therapy in the treatment of de novo acute myeloid leukemia (AML), 48 patients with newly diagnosed AML, aged 35 (14-57) years, were entered into this clinical study. The median followup was 26 months. Eighty-three percent of patients achieved complete remission (CR), and the first single course of induction HAA regimen resulted in CR rate of 79%. The CR rate of 100, 82 and 33% were achieved in patients with favorable, intermediate and unfavorable cytogenetics, respectively. For all patients who achieved CR, the median time from the initiation of the induction therapy to the evaluation of the remission status was 32 days. For all patients, the estimated 3 years overall survival (OS) rate was 53%, whereas for patients with M5, the estimated OS rate at 3 years was 75%. The toxicities associated with HAA regimen were acceptable, and the most common toxicity was infection. This study suggested that HAA regimen might be a well-tolerable, effective induction regimen in young adult patients with AML.
Introduction
Twenty years ago, Cancer and Leukemia Group B (CALGB) 1 introduced the induction regimen containing 3 days of daunorubicin and 7 days of cytarabine (Ara-C) in the treatment of adult patients with de novo acute myeloid leukemia (AML), which subsequently was chosen as the standard induction remission regimen. Since that time, a considerable amount of strategy has been employed to improve the antileukemic efficacy of this regimen. Those strategies included substituting alternative anthracyclines such as idarubicin, [2] [3] [4] adding or substituting high-dose cytarabine; [5] [6] [7] adding a third agent such as etoposide. [8] [9] [10] Although cumulative studies do suggest a better disease-free survival, however, superiority over conventional chemotherapy still has not been demonstrated. Recent trial by the Australian Leukemia and Lymphoma Group (ALLG) 11 employed idarubicin, etoposide and high-dose of Ara-C in both induction and consolidation therapy for AML.
Complete remission (CR) was achieved in 80% patients, with relapse-free survival (RFS) at 3 years of 49%, but also with severe toxicities such as 10% of early death (ED) rate, and 11% hepatic-bilirubin, 7% central nervous system, 4% renal toxicities of WHO grade III-IV occurred during induction therapy. Those toxicities together with multidrug resistance established the major barriers to higher rate of CR and long-term remission.
Finding new agents that might overcome multidrug resistance and decrease toxicities has thus been actively pursued. Homoharringtonine (HHT) is a drug that primarily inhibits protein synthesis. Its cytotoxicity is cell-cycle specific, mainly affecting cells in the G1 and G2 phases. 12 Studies in vitro 13, 14 showed that HHT inhibited colony formation by 50% in variety of acute myeloid cell lines as well as in fresh myeloid leukemic cells in a dose-dependent manner. It is notable that the murine P388 leukemia cells that are resistant to doxorubicin, vincristine and cytarabine were sensitive to HHT. 15 Moreover, other investigators 16 demonstrated that HHT had significant potential synergistic effects with cytarabine. Later, clinical studies in vivo were conducted and showed that with HAT (HHT, cytarabine and thioguanine), DAT (daunorubicin or doxorubicin, cytarabine and thioguanine), the CR rate of 68% and 20 months of survival duration 17 were achieved in patients with AML. Aclarubicin, an alternative to daunorubicin, had promising antileukemic efficacy in combination with cytarabine. 18 The above encouraging results and our experience with HHT used in AML for 30 years prompted us to combine HHT, aclarubicin and Ara-C to establish a pilot induction regimen, abbreviated as HAA, whose efficacy and toxicity were assessed in current study.
Patients and methods

Patients
Between April 2001 and September 2003, 48 patients with newly diagnosed AML who admitted to the Department of Hematology, the First Affiliated Hospital, Zhejiang University College of Medicine entered this clinical trial. All the eligible patients fulfilled the following criteria: the diagnosis of AML was established according to the standard French-American-British (FAB) cytologic and cytochemical criteria, 19 with an exception of FAB M3 (acute promyelocytic leukemia); age 14 years or older; no major comorbidity (no evidence of cardiac disease); immune phenotyping performed; and informed consent obtained. The study protocol was approved by the hospital ethical board. Patients with karyotypes of t(8;21), inv(16), or t(16;16) were considered to have good-risk cytogenetics; À5, À7, del(5q), abnormal 3q, or complex cytogenetics, defined as the presence of at least five unrelated cytogenetic abnormalities, were considered to be the karyotypes with poor-risk cytogenetics; patients with normal cytogenetics and other miscellaneous single abnormalities were defined as having intermediate-risk cytogenetics. Characteristics of the study group are listed in Table 1 .
Antileukemic therapy
The HAA regimen consisted of HHT, Ara-C and aclarubicin. HHT was administered at a dose of 4 mg/m 2 by continuous infusion over 4 h daily (or 2 mg/m 2 intramuscular injection twice daily) for 3 days (days 1-3), Ara-C was given at a dose of 75 mg/m 2 twice daily (the daily dose was 150 mg/m 2 ) for 7 days (days 1-7) and aclarubicin was administered at a dose of 12 mg/m 2 daily by continuous infusion over 2 h for 7 days (days 1-7). All patients were treated with identical induction chemotherapy, except for the reasons of unacceptable toxicity (grades III-IV) (i.e., cardiovascular complications with HHT or aclarubicin) or patient choice. Toxicity was graded according to the National Cancer Institute common toxicity criteria. 20 Upon recovery of the periphery blood count, a bone marrow aspirate was performed to assess the status of the response, and the exact day when bone marrow aspirate was examined was at the discretion of the treating physicians. Patients who achieved CR received consolidation therapy. For patients with partial remission (PR), the same induction HAA regimen was repeated, whereas for patients with non-remission (NR) after the first course of induction therapy or with PR/NR after two courses of induction therapy, the second line induction therapy was administered. Granulocyte colony-stimulating factor 5 mg/kg, subcutaneously, daily was administered from the day neutrophil count was o0.5 Â 10 9 /l until the day neutrophil count was 41.0 Â 10 9 /l on 3 successive days. Antibiotic and antifungal treatment and supportive care were given according to commonly used guidelines.
Consolidation therapy included one course of the same HAA regimen as used in induction therapy, and was applied 2-4 weeks after achievement of CR. 
Response criteria
CR was defined by a bone marrow with normal hematopoiesis, including neutrophils 41.5 Â 10 9 /l, platelets 4100 Â 10 9 /l, blasts in bone marrow o5%, no blasts in peripheral blood and no extramedullary disease. PR was defined by a bone marrow blasts 5-20% and peripheral blood blasts o5% with neutrophils 41.5 Â 10 9 /l, platelets 450 Â 10 9 /l, lymphoid nodes o2 cm, splenomegaly o2 cm below left costal margin, hepatomegaly o5 cm below right costal margin and considerable improvement of performance status. NR was established for patients who did not fulfill the above criteria. ED was defined as death following induction treatment before it was possible to assess the remission status.
All patients underwent full clinical examinations and assessment of blood counts. Liver and kidney function was tested before each course of chemotherapy. As a routine, electrocardiograms (ECG) and blood culture were obligatory for all patients before and after each course of chemotherapy during induction, consolidation and maintenance phases. Ultrasound cardiography and Holter monitoring were performed in those cases who were suspected to have cardiac problem after either ECG or clinical manifestation. The remission status was assessed after completion of each course of induction and consolidation therapy. During the maintenance phase, it was performed at the discretion of the treating physician.
Statistical methods
Overall survival (OS) was defined as the time from the start of the treatment to death owing to any causes, RFS was the time interval from the date of achieving CR to the first event of either a relapse or death in CR, whichever occurred first. OS and RFS were estimated using the Kaplan-Meier method. 21 The duration of the initiation of the induction therapy to the evaluation of the remission status was compared using Mann-Whitney U-test. Statistical analyses were carried out using SPSS (12.0).
Results
Patients
A total of 48 patients, aged 35 (range 14-57 years) years, with 15 male and 33 female patients, were enrolled in this study. All but one patient had cytogenetic study. Thus, karyotype was established in 47 patients, with 11 cases having favorable cytogenetics, 33 having intermediate cytogenetics and three (13/18) , and a second course of HAA regimen resulted no additional CR, so, the overall CR rate for M5 patients was 72%, too. It was notable that all two patients in this study who were defined as ED came from M5 group ( Table 2) .
All 11 patients with favorable cytogenetics achieved CR (100%). Of the 33 patients with intermediate cytogenetics, 27 (82%) achieved CR, whereas of the three patients with unfavorable cytogenetics, one (33%) patient obtained CR.
The median time from the initiation of the induction therapy to the evaluation of the remission status in patients who achieved CR after a single induction course was 30 (18-65) days versus 56 (55-60) days in patients who achieved CR after two induction courses (Po0.01). For all patients who achieved CR, the median time from the initiation of the induction therapy to the evaluation of the remission status was 32 days.
Toxicity
The most common toxicities during induction phase were infections. Of all 48 patients, 43 (90%) patients had various degree of infections (etiology: bacterial -21%, fungal -21%, mixed -9%, negative culture -49%), and 16 (33%) patients had severe (grades III-IV) infections (etiology: bacterial -19%, fungal -13%, mixed -6%, negative culture -62%). Most patients with infections manifested as pneumonia and acute bronchitis and tracheitis (56%). The most severe toxicities were cerebral bleedings, which occurred in two patients (4%) and led both patients to death. Another bleeding event occurred as ocular hemorrhage, which was controlled with the administration of platelets transfusion. Grade III-IV nausea and vomiting (6%) and gastrointestinal toxicity (6%) were entirely reversible (Table 3) .
On day 6 of the first induction therapy, one patient (2%) developed tachycardia and palpitation, thus he did not receive further aclarubicin, but continued receiving cytarabine. ECG showed slight escalation of ST-T wave. On day 29, Holter monitoring showed short runs of ventricular tachycardia, ultrasound cardiography indicated slightly decreased LF/AF. On day 32, patient achieved CR, and on day 54, he recovered from cardiac disturbance. Until the closeout date, with a follow-up of 50 months, patient was still alive. The other WHO grade I-II toxicities included transient liver dysfunction (4%), drug fever (4%), fluid retention (2%), depression (2%) and hyperglycemia (2%). No hypotension was observed.
Within induction therapy, severe granulocytopenia and thrombocytopenia occurred in all patients. The median minimal Table 2 Antileukemic efficacy There was one patient in this group who achieved CR after second line chemotherapy (idarubicin plus DA regimen) but did not be included in the CR rate above. Abbreviations: 1 CR, complete remission with a single HAA induction course; 2 CR, complete remission after two courses of HAA induction therapy; OS, overall survival; RFS, relapse-free survival.
Table 3
Non-hematological and hematological toxicity during induction treatment
Values
Non-hematological toxicity (WHO grades III-IV))
Infections (n) 16 (33%) Nausea and vomiting (n) 3 (6%) Bleeding (n) 3 (6%) GIT (n) a 3 (6%)
Hematological toxicity
Median minimal neutrophil count Â neutrophil count amounted to 0.5 (0.1-1.2) Â 10 9 /l, and the interval from the start of the induction therapy to the day when neutrophil count began to be less than 1 Â 10 9 /l was 14 days, and the duration of neutrophil count less than 1 Â 10 9 /l was 12 days. The median minimal platelets were 5 Â 10 9 /l, and the interval from the start of the induction therapy to full recovery of the platelets (100 Â 10 9 /l) was 24 days (Table 3) .
Follow-up results
Of all the 48 patients, four patients were lost to follow-up: two patients achieving CR after the first induction therapy refused to continue receiving further therapy and were lost to follow-up, the third one was the only PR patient in this study who still had 7.5% blasts in bone marrow after two courses of HAA induction therapy and another patient came from NR group who had 37% blast cells in bone marrow after the first course of induction therapy. So, with an exception of two ED patients, there were 42 patients kept to follow-up. Among the 42 patients, there were four cases who were in NR group, and all died 3-8 months later. Among the remaining 38 patients, who all were in CR group, there were three patients who died of variety of disease: the first died of graft-versus-host disease related to allogeneic stem cell transplantation received shortly after achieving CR, the second died of severe sepsis during consolidation therapy and the last died of complications of kidney dysfunction related to chemotherapy during maintenance phase. Then, among the still remaining 35 CR patients, there were 14 cases relapsed, after a median time of 13 months, and 21 patients being alive without disease. Of the above 14 patients, 12 patients died subsequently, fortunately, another two patients were still alive by the time of closeout, with one of the two patients obtaining CR again, and another one sustaining NR. By the time of closeout, with a median follow-up of 26 months, for the 42 patients, the estimated 3 years OS rate was 53% (Figure 1 ), and for those 38 patients who achieved CR, the estimated RFS at 3 years was 52% (Figure 2 ). According to cytogenetic risk group, the estimated 3 years OS rate was 52 and 61%, for the intermediate and favorable cytogenetic groups, respectively. For patients with unfavorable cytogenetics, the estimated 3 years OS time was 5.5 months only (Figure 3 ). For the patients with M5, both the estimated OS and RFS at 3 years were 75%, whereas for the non-M5 patients, 44% of estimated 3 years OS rate and 40% of 3 years RFS were achieved (Figures 4 and 5) ( Table 3) .
In this study, there were only two patients who received allogeneic stem cell transplantation. Besides the above-mentioned one, the second was a patient with M2a who obtained CR after two courses of HAA induction therapy and relapsed 11 months later. He was then given a rescue allogeneic stem cell transplantation, but died of graft-versus-host disease. The patient who had 34% blast cells in bone marrow after the first HAA induction therapy and achieved CR after two courses of IDA therapy relapsed 5 months later and died subsequently. All but three patients who achieved CR (except for those patients who were lost to follow-up and died early) received consolidation and maintenance therapy. Those three patients refused to continue receiving remaining maintenance therapies after 3, 4, 5 courses of maintenance treatment, respectively, and it was notable that those three patients had survived by the time of closeout for 23, 34 and 48 months, respectively, without relapse, even with higher quality of life. Of all the 36 CR patients after a single course of HAA induction therapy, who were kept to follow-up, 10 cases relapsed after a variety of periods of CR and only one of the 10 patients survived with not achieving CR again, while of the two cases who achieved CR after two courses of HAA induction therapy and were kept to follow-up, both two patients relapsed, fortunately, one of the two achieved CR again and had survived until the time of closeout of this study for 44 months, another one died subsequently.
Discussion
This study was carried out to evaluate the efficacy and the toxicity of the original HAA regimen in the treatment of younger adult de novo AML. Our previous study 22 has explored the use of HA (homoharritonine 4 mg/m 2 /day, days 1-3; cytarabine 150 mg/m 2 /day, days 1-7) during induction treatment for adult AML (with an exception of M3, but including AML patients arising from myelodysplastic syndrome and aging more than 60 years). Of all the 146 AML patients, 65 (44.5%) patients achieved CR with a single HA induction course versus 34/78 (43.6%) of CR rate produced by a single standard DA induction treatment. In the present study, the CR rate of 79% with a single induction course was achieved in younger adult patients with de novo AML, and the overall CR rate was 83%. As we know, in patients of comparable age treated with standard dose, or even high dose, induction regimen, typically 75-80% CR rate and less than 77% CR rate with a single induction course 2-11 usually were achieved. So, the CR rate of 83% in this study was a quite good result. In order to assess the mechanism for HAA regimen, bone marrow samples (stored at À801C) from five patients (two with CR after the first induction course, one CR after two HAA induction courses, one NR and one ED) were available and were investigated for the expression of mdr-1 gene by reverse transcriptase-polymerase chain reaction. All the five patients were positive for mdr-1 (data not shown). This result suggested that mdr-1 gene might be expressed in majority of the patients involved in this study. Together with the results reported by other authors, 15 the HAA activity in this study may be associated with the effect of overcoming the multidrug resistance of leukemia cells. As the precise mechanism for HAA regimen is yet to be elucidated, we also postulated that the synergistic effects 16, 18 among HHT, Ara-C and aclarubicin might play some role.
For patients with newly diagnosed adult non-promyelocytic AML, the standard approach includes the induction therapy with 3 days of anthracycline and 7 days of cytarabine followed by risk-adapted post-remission therapy. 23 Based on risk-adapted strategy, patients with favorable cytogenetics should receive intensive chemotherapy; for those with unfavorable cytogenetics, allogeneic transplant is the best option; for patients with intermediate-risk cytogenetics, either intensive chemotherapy, high-dose chemotherapy with autologous stem cell rescue or sibling-matched allogeneic transplant is suitable. However, in the setting where this study was conducted, bone marrow or stem cell transplantation, even intensive consolidation and maintenance therapy was not easily available for many patients owing to family economic conditions. Only two out of 48 enrolled patients in this study received allogeneic stem cell transplantation. It was interesting that 53% of OS rate at 3 years that were comparable to that reported for standard approach [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] (such as 49% of OS rate at 3 years in a study by Bradstock et al.
11
) were achieved. Considering the comparable distributions of the cytogenetic risk group in current study (favorable: 23%, intermediate: 69%, unfavorable: 6%, unknow: 2%) with those in other study 11 unfavorable: 7%, unknow: 6%), these results were encouraging. In a clinical trial conducted by the Eastern Cooperative Oncology Group, 24,25 of 1414 de novo AML patients who were observed over 18 years, 660 (76%) relapsed or died. In this study, of 38 CR patients, with a median follow-up of 24 months, 14 (37%) patients relapsed after a median time of 13 months. It is difficult to compare these two relapse rates because of differences of many factors, such as age, FAB subtype and so on, between the two studies. As cumulative data [26] [27] [28] demonstrated that the time to CR from the start of the induction therapy is a major independent prognostic factor for long-term outcome in AML, we calculated the interval in this study. The results showed that the median time from the initiation of the induction therapy to the first achieving of CR was 32 days, which was shorter than 37-40 days reported in other observations. 29 Thus, it is reasonable to postulate that the higher long-term remission rate in this study might be due to the short time to CR and high CR rate after a single course of induction therapy.
Analysis of data from this study taking into account cytogenetic risk group showed that karyotypes at diagnosis remained the important prognostic factors that could predict CR rate and long-term perspectives. For the patients with favorable cytogenetics, HAA regimen produced 100% CR rate and 61% OS at 3 years, whereas for the patients with unfavorable cytogenetics, only 33% CR rate and 5.5 months of OS at 3 years were achieved. These results are comparable to those obtained from high-dose induction regimen. Notably, for patients with unfavorable cytogenetics, HAA regimen had no superiority over standard induction therapy. These results indicated that the antileukemic efficacy of HHT for those patients with unfavorable cytogenetics was limited.
Considering that there were 18/48 (37.5%) M5 patients in the current study group, the efficacy of HAA for M5 versus non-M5 patients were observed. There was no significant difference in the CR rate and OS at 3 years in M5 versus non-M5 (72 versus 90%, 75 versus 44%, respectively). In the study conducted by the Eastern Cooperative Oncology Group, 24 of 138 M5 patients, only 14 patients (10%) survived for X3 years. In this study, the OS at 3 years reached 75%. Based on these results, it is reasonable to say that HAA regimen might be a good choice for M5 patients.
In a phase I study, 30 when HHT was administered at a bolus dose of 5-6 mg/m 2 daily using a short infusion schedule, the cardiovascular failure occurred in 25% patients. In a continuous infusion schedule, 31 at a dose of 5 mg/m 2 for 9 days, cardiovascular complications, including hypotension and tachycardia, were reduced significantly. Aclarubicin was also an agent which can induce QTc prolongation leading to ventricular fibrillation. 32 It was obvious that the combination of the two heart-injuring agents might lead to more cardiac disturbance. So in this trial, HHT was given at a lower dose of 4 mg/m 2 over 4 h infusion for 3 days, and aclarubicin was administered at a lower dose of 12 mg/m 2 /day for 7 days as a 30-min infusion (for aclarubicin, the routine dose was 60 mg/m 2 /day for 5 days 30 ). Results from this observation showed that only one patient developed tachycardia and palpitation, which was recovered completely later. The other non-hematological toxicities included 6% cerebral bleeding, which in some cases directly resulted in ED (4% of ED rate). Most of those toxicities were reversible and curable. Liver dysfunction, drug fever, fluid retention, depression and hyperglycemia occurred only in less than 4% patients were mild and transient. Severe granulocytopenia and thrombocytopenia occurred in all patients during induction therapy. The median duration of 12 days of nadir neutrophil count in the current cohort was shorter as compare with that of 19 days reported by other investigators. 33 Overall, compared with others, the toxicities associated with HAA regimen were more acceptable.
In summary, HAA regimen is a well-tolerable and effective induction regimen for patients with de novo AML. Both the CR rate, especially that achieved after the first course of induction therapy, and the OS and RFS at 3 years in this study were encouraging, although the antileukemic activity in patients with unfavorable cytigenetics was limited. As this study was a phase II clinical trial, to provide adequate justification for the above observation, further investigation with a randomized phase III trial is warranted.
